Pfizer Inc. (NYSE:PFE) Shares Acquired by Donaldson Capital Management LLC

Donaldson Capital Management LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 1.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,694 shares of the biopharmaceutical company’s stock after buying an additional 410 shares during the period. Donaldson Capital Management LLC’s holdings in Pfizer were worth $947,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in PFE. Staley Capital Advisers Inc. raised its position in Pfizer by 3.5% during the 4th quarter. Staley Capital Advisers Inc. now owns 2,150,418 shares of the biopharmaceutical company’s stock worth $57,051,000 after buying an additional 73,594 shares during the last quarter. Miller Financial Services LLC purchased a new position in Pfizer in the fourth quarter worth $431,000. King Luther Capital Management Corp lifted its holdings in Pfizer by 1.4% in the fourth quarter. King Luther Capital Management Corp now owns 2,535,085 shares of the biopharmaceutical company’s stock valued at $67,256,000 after acquiring an additional 34,070 shares during the period. Citizens Financial Group Inc. RI lifted its stake in shares of Pfizer by 9.9% in the fourth quarter. Citizens Financial Group Inc. RI now owns 334,663 shares of the biopharmaceutical company’s stock valued at $8,879,000 after purchasing an additional 30,186 shares during the period. Finally, Sage Mountain Advisors LLC grew its holdings in shares of Pfizer by 7.3% in the 4th quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 1,404 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $26.00 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $147.33 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a 50-day moving average of $26.29 and a two-hundred day moving average of $27.19.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Shareholders of record on Friday, January 24th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.62%. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on PFE shares. Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Guggenheim restated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.